Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.
Bradley Monk, MD
Trebananib added to paclitaxel significantly improved progression-free survival (PFS) in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial. The addition of trebananib to paclitaxel achieved a 52% prolongation in time-to-disease progression or death, with a median PFS of 7.2 months, versus 5.4 months with placebo (P<.001).
Trebananib (formerly AMG 386) is an investigational antiangiogenesis recombinant peptide that inhibits the binding of angiopoietin 1 and 2 to the Tie2 receptora different target than that of bevacizumab, a VEGF-receptor inhibitor commonly used to treat ovarian cancer.
“Anti-VEGF therapy creates a constellation of adverse events. In the TRINOVA series, the idea is to target a non-VEGF angiogenesis factor angiopoeitin 1 and 2. This strategy has been shown to delay tumor growth and shrink tumors,” explained Bradley Monk, MD, Creighton University School of Medicine and University of Arizona Cancer Center at St. Joseph’s Hospital in Phoenix. Monk reported these results at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), held in Amsterdam, The Netherlands, September 27 to October 1.
“This was a rigorous and closely audited clinical trial conducted at 179 sites in 32 countries. Today we present the primary PFS analysis and the interim overall survival [OS] analysis. Next year we hope to have the final OS data,” he told listeners.
Patients enrolled in the phase III trial (N = 919) received up to three prior therapies and had recurrent disease within less than 12 months of their last prior therapy. They were randomized to a 3-weeks-on/1-week-off regimen of weekly paclitaxel, with one arm receiving paclitaxel plus placebo and the experimental group being treated with paclitaxel plus once-weekly trebananib 15 mg/kg IV.
The average age of patients was about 60 years, and most were Caucasian. Treatment arms were well balanced for disease and demographic factors. The majority had grade 2-3 cancers; 40% failed on one prior therapy; 40% failed on two; and 20% failed on three.
In addition to the primary endpoint of PFS in the overall trial, trebananib improved PFS in all subgroups. Response rate was improved from 30% with placebo to 38% with trebananib. Most responses were deemed partial responses. At the interim survival analysis, the OS difference favoring trebananib is about 2 months, but only half of the survival events have occurred.
Discontinuations were mostly due to disease progression: 87% in the placebo group versus 82% in the trebananib group.
Adverse events of any grade occurred in 96% of placebo patients and 97% of trebananib patients. Edema was the major toxicity of trebananib, experienced by 26% of patients in the control group versus 57% with trebananib (any grade); 5% of the trebananib group had edema of Grade 3 or higher. The incidence of nausea and vomiting was similar in both groups.
In TRINOVA-1, the side-effect profile of trebananib did not show increased class effects of VEGF-R inhibition. “The side-effect profile of anti-angiopoetin therapy is not similar to that of anti- VEGF therapy [ie, hypertension, proteinuria, wound-healing, complications, and arterial thrombotic events],” said Monk.
Neutropenia and anemia were more common in the placebo arm, and neurotoxicity was more common in the trebananib arm. Monk explained that this was thought to be related to increased cycles of paclitaxel.